| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/05/2005 | US20050095290 comprising pharmacologically active substance, drug absorbefacient and taurine compound or polyamine; suppressing or preventing damage of the intestinal mucous membrane |
| 05/05/2005 | US20050095288 Compressed core comprising guaifenesin; pseudoephedrine or phenylephrine or salt; controlled release coating |
| 05/05/2005 | US20050095279 Transdermal analgesic systems having reduced abuse potential |
| 05/05/2005 | US20050095277 Neuropathy cream |
| 05/05/2005 | US20050095262 Multivitamin syrup for children or young adults |
| 05/05/2005 | US20050095249 Protein markers for lung cancer and use thereof |
| 05/05/2005 | US20050095248 Use of inhibitor of cathepsin S based upon peptide sequence which comprises at least about 2-20 consecutive residues from preferred invariant chain cleavage site of cathepsin S, spanning from residue 68 to residue 90 of specified sequence |
| 05/05/2005 | US20050095239 Methods and compositions for treating Alzheimer's disease |
| 05/05/2005 | US20050095232 Vaginal care composition |
| 05/05/2005 | US20050095229 Comprises conduit connected to blood pool, cell culture for producing analyte (insulin, glucagons, and/or somatostatin), and concentration controller (integrated circuit) |
| 05/05/2005 | US20050095228 Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
| 05/05/2005 | US20050095226 Down-regulation of DNA repair to enhance sensitivity to p53-mediated suppression |
| 05/05/2005 | US20050095196 Increasing blood permeability to capillary or arterial cells of abnormal brain region |
| 05/05/2005 | US20050092969 Coating with oil or water insoluble material to make both constituents coexist in oily or aqueous medium respectively |
| 05/04/2005 | EP1528058A1 Polymorphic crystalline forms of celecoxib |
| 05/04/2005 | EP1527786A1 Tissue volume reduction |
| 05/04/2005 | EP1527778A1 Methods of enhancing opiate analgesic potency or detoxifying an opiate addict |
| 05/04/2005 | EP1527343A2 Organic compounds |
| 05/04/2005 | EP1527196A2 Treatment for asthma or allergies |
| 05/04/2005 | EP1527189A2 Mutant proteinase inhibitors and uses thereof |
| 05/04/2005 | EP1527178A2 Novel class ii cytokine receptors and uses thereof |
| 05/04/2005 | EP1527171A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 05/04/2005 | EP1527084A2 Promoters exhibiting endothelial cell specificity and methods of using same |
| 05/04/2005 | EP1527074A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 05/04/2005 | EP1526895A2 Methods for treating carbonic anhydrase mediated disorders |
| 05/04/2005 | EP1526870A1 Novel combination of glucocorticoids and pde-4-inhibitors for treating respiratory diseases, allergic diseases, asthma and copd |
| 05/04/2005 | EP1526869A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 05/04/2005 | EP1526863A2 Using heat shock proteins to increase immune response |
| 05/04/2005 | EP1526860A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 05/04/2005 | EP1526858A2 Use of gaba-c receptor antagonists for the treatment of myopia |
| 05/04/2005 | EP1526850A2 Compositions intended for the treatment of peripheral neuropathies, preparation thereof and uses of same |
| 05/04/2005 | EP1526847A2 Pharmaceutical dosage form comprising a sulfite compound |
| 05/04/2005 | EP1526846A2 Gelatin capsule exhibiting reduced cross-linking |
| 05/04/2005 | EP1526845A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 05/04/2005 | EP1526844A2 Pellicle-resistant gelatin capsule |
| 05/04/2005 | EP1377164A4 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
| 05/04/2005 | EP1317448B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/04/2005 | EP1297121B1 Purging of cells using viruses |
| 05/04/2005 | EP1240165B1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| 05/04/2005 | EP1206256B1 Combination therapy using pentafluorobenzenesulfonamide and platin compound |
| 05/04/2005 | EP1140830B1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5ht1a receptor activity |
| 05/04/2005 | EP1140001B1 Composition for treatment of burns |
| 05/04/2005 | EP1139752B1 Methods and compositions for treatment of cell proliferative disorders |
| 05/04/2005 | EP1023067B1 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
| 05/04/2005 | CN1613012A Soluble cd40l (cd154) as a prognostic marker of atherosclerotic diseases |
| 05/04/2005 | CN1612942A Viral capsid assembly intermediates |
| 05/04/2005 | CN1612939A Highly sensitive and continuous protein tyrosine phosphatase test using 6, 8-difluoro-4-methylumbelliferyl phosphate |
| 05/04/2005 | CN1612875A 5-(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active |
| 05/04/2005 | CN1612763A Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 05/04/2005 | CN1612756A Composition and method for treatment of wounds |
| 05/04/2005 | CN1612751A Combination treatments for allergic disease comprising administering an anti-IgE antibody and antiallergic compound |
| 05/04/2005 | CN1612746A Use of HEPCIDIN as a regulator of iron homeostasis |
| 05/04/2005 | CN1612745A Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 05/04/2005 | CN1612743A Herbal composition phy906 and its use in chemotheraphy |
| 05/04/2005 | CN1612739A Method for treating or preventing inflammatory diseases |
| 05/04/2005 | CN1612736A Imidazo (4, 3-e)-1, 2, 4-triazolo(1, 5-c) pyrimidines as adenosine A2A receptor antagonists |
| 05/04/2005 | CN1612731A Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases |
| 05/04/2005 | CN1612725A Injectable depot composition |
| 05/04/2005 | CN1612724A Vascular occlusion solid-phase agent with immobilised platelet binding agent |
| 05/04/2005 | CN1199695C Composition with carbohydrate matrix contaniing liposoluble substance |
| 05/04/2005 | CN1199644C Medicine for treatment of accidental extravasation of anthryracyclines |
| 05/04/2005 | CN1199636C Use of 15-deoxysperguallin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases |
| 05/04/2005 | CN1199621C Device and medicine for treatment of dysmenorrhea |
| 05/03/2005 | US6888043 Feminine care products for the delivery of therapeutic substances |
| 05/03/2005 | US6888016 For therapy of insulin resistance; for stimulating the glucose up-take in adipocytes |
| 05/03/2005 | US6887987 DNA encoding the human serine protease T |
| 05/03/2005 | US6887892 Tricyclic derivatives of indole with antiangiogenic activity |
| 05/03/2005 | US6887889 Aryl and biaryl piperdines with MCH modulatory activity |
| 05/03/2005 | US6887886 Therapeutic compositions comprising excess enantiomer |
| 05/03/2005 | US6887879 Pharmaceutical combination of antiviral agents |
| 05/03/2005 | US6887877 Viricide for hepatitis virus |
| 05/03/2005 | US6887876 Benzamidine derivatives |
| 05/03/2005 | US6887871 Use of phenylheteroakylamine derivatives |
| 05/03/2005 | US6887870 Useful as antianginal and cardioprotective agents; for therapy and prophylaxis of angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia |
| 05/03/2005 | US6887858 Method of treating dry eye disease with purinergic receptor agonists |
| 05/03/2005 | US6887844 To stimulate the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM) |
| 05/03/2005 | US6887707 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
| 05/03/2005 | US6887704 A cell population cultured ex-vivo in a culture medium under conditions permitting cells of cell population to proliferate and at the same time reducing capacity of cells in utilizing copper, hence expanded yet not further differentiated |
| 05/03/2005 | US6887680 Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays |
| 05/03/2005 | US6887676 For diagnosis/therapy/prevention of Creutzfeldt-Jacob disease |
| 05/03/2005 | US6887674 Artery- and vein-specific proteins and uses therefor |
| 05/03/2005 | US6887670 For drug screening; solid phase synthesis; fusion proteins; genetic engineering |
| 05/03/2005 | US6887502 Compositions comprising fat soluble substances in a glassy carbohydrate matrix |
| 05/03/2005 | US6887499 Mixture of jasmone compound, antioxidant and carnitine |
| 05/03/2005 | US6887497 Composition for the treatment and prevention of osteoarthritis, rheumatoid arthritis and improved joint function |
| 05/03/2005 | US6887489 Propionibacterium P-63 for use in direct fed microbials for animal feeds |
| 05/03/2005 | US6887474 Compositions and methods for producing vascular occlusion |
| 05/03/2005 | US6887473 Administering as antitumor, antimetastasis, antiinflammatory, or anticarcinogenic agent |
| 05/03/2005 | US6887468 Antibody kits for selectively inhibiting VEGF |
| 05/03/2005 | CA2486473A1 Vaginal care composition |
| 05/03/2005 | CA2245397C Antitumor agent |
| 04/28/2005 | WO2005038056A1 Combination therapy for the treatment of viral diseases |
| 04/28/2005 | WO2005038028A1 Poxvirus vector encoding retrovirus (eg hiv) and cytokine |
| 04/28/2005 | WO2005038027A1 Transgenic nonhuman mammal |
| 04/28/2005 | WO2005037995A2 Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy |
| 04/28/2005 | WO2005037928A2 Compounds for dual photodiagnosis and therapy |
| 04/28/2005 | WO2005037318A2 Treatment of arthritic conditions, chronic inflammation or pain |
| 04/28/2005 | WO2005037317A2 Mast cell-derived renin |
| 04/28/2005 | WO2005037316A1 Method of inhibiting secretase activity |
| 04/28/2005 | WO2005037315A1 Therapeutic agent for mesothelioma |